



24th October 2025

Vitasora to Expand MSSP services into Evolent's rural markets as Evolent Care Partners Joins Privia Health

Highlights

- Expanded Vitasora services to generate an estimated **US\$12-US\$18M** in Annualised recurring revenue.
- Vitasora to begin scaling Care Management services beyond Hawaii into Evolent's multi-state U.S. footprint
- Vitasora initial target is **20,000–30,000 patients** in 2026 targeting rural populations under the ACO under Medicare MSSP and Medicare FFS models.
- Evolent Health Inc., owner of Evolent Care Partners (ECP), has announced the divestiture of ECP to Privia Health Group (NASDAQ: PRVA), a physician-led organization with **~1,500,000 lives** under management and one of the highest-performing ACO portfolios in the U.S.
- **Privia's ~1,500,000-member portfolio** represents a significant upside opportunity as programs scale

Vitasora Health Limited (ASX: VHL) ("Vitasora" or "the Company"), a leader in AI-powered Connected Care solutions, is pleased to announce the expansion of its agreement with Evolent Care Partners (owned by Evolent Health, NYSE: EVH) to deliver Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) services across the U.S. mainland, following success with its Hawaii program.

The Hawaii pilot, launched in 2024, is to provide continuous connected care to Evolent Care Partners (ECP) members and drive measurable improvements in outcomes and provider satisfaction. Evolent highlighted the success of its partnership with Vitasora in Hawaii as a key driver of the decision to expand nationally.

Evolent Care Partners Joins Privia Health (NASDAQ: PRVA)

Evolent Health Inc., owner of Evolent Care Partners (ECP) and Vitasora's partner, has announced the divestiture of ECP, its value-based primary care business, to **Privia Health Group (NASDAQ: PRVA, market cap ~USD3B)**. Privia is a physician-led national healthcare organization that has built its reputation on supporting independent practices. With ~1.5M lives under management and one of the highest-performing ACO portfolios in the United States, Privia brings resources, technology, and capital that will enable ECP to expand its impact while ensuring independent physicians remain at the center of value-based care.

ECP has increasingly become the MSSP of choice for independent primary care providers, demonstrated by ~100% growth over the past two years, including patients in Hawaii where Vitasora already provides CCM services. Its proven track record of high performance and unique value to member organizations makes it a standout in the U.S. healthcare market.

For Vitasora, the combination of ECP and Privia provides a significantly larger platform to scale services across multiple states and patient populations.



Program Scope & Revenue Impact

- **Initial States:** Expansion across 10–15 U.S. mainland states (subject to contracting and rollout)
- **Target Providers:** Thousands of independent primary care physicians within ECP and possibly Privia networks
- **Patient Population:** 20,000–30,000 patients in the initial rollout in 2026, with the potential to expand materially across Privia’s ~1.5M-member portfolio
- **Annualised Revenue Forecast:** ~US\$12–18 million, depending on care mix (US\$35–US\$70 PPM)
- **Go-Live Timeline:** Nationwide execution-ready within 60–90 days
- **Revenue Realisation:** Revenue expected to commence **30–60 days post-enrolment**, with meaningful contribution beginning in **H1 CY2026** and scaling progressively as additional states are onboarded

Forecast Milestone Timeline

Quarter	Milestone	Revenue Impact
Q4, CY25	Execution, roll out planning & engagement	No material revenue
Q1 & Q2 CY26	Initial patient enrolments in first wave of states	1 st revenue 30-60 days post-enrolment
Q3 & Q4 CY26	Broader rollouts; enrolment scaling to 20,000 - 30,000 lives	Ramp-up in ARR; approaching run-rate of US\$12–18M pa
CY2027+	Potential expansion into wider Privia footprint (~1.5M lives)	Significant upside opportunity tied to national portfolio

What This Means for Vitasora

- Validates Hawaii pilot relationship and positions Vitasora for nationwide scale
- Provides a clear pathway to expand into new states where connected care can reduce costs and improve patient outcomes
- Significant revenue opportunities in 2026, **US\$12M-US\$18M ARR**
- Opens new possible opportunities to collaborate with Privia’s leadership and leverage their resources to accelerate adoption

Marjan Mikel, CEO of Vitasora, said: “Our Hawaii program has demonstrated the power of connected care when supported by committed provider networks. While there is still work ahead to ensure the seamless rollout of this clinical program across the US, the Evolent expansion represents a highly significant revenue opportunity for Vitasora, that is pivotal to our path to profitability and further substantial revenue growth in 2026.”

Outlook

The expansion of Vitasora’s engagement with Evolent / ECP, paired with the opportunity created by the ECP integration into Privia Health, represents one of the most significant U.S. growth opportunities in the Company’s history. It affirms Vitasora’s partner status with leading value-based care organizations and provides a pathway to scale across multiple states, providers, and patient populations.



Further updates on contracted states, patient volumes, and revenue impact will be provided as programs move into execution.

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Vitasora Health Limited
P: +61 408 462 873
E: marjan@vitasorahealth.com

Mr Nicholas Smedley
Non-Executive Chairman
Vitasora Health Limited
P: +61 447 074 160
E: nicholas@vitasorahealth.com

This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:VHLUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.vitasorahealth.com.au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respi™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respi.co/us/> or for [wheezo®](#)

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora's current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.